Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.11.13 (
protein kinase C
)
49,245
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The proteolytic processing and secretion of
APP
are regulated by protein phosphorylation, especially via
protein kinase C
and protein phosphatases 1 and/or 2A. Our studies of these regulatory mechanisms have led us to perform extensive experimentation on the metabolism of
APP
carboxyl-terminal fragments, using as our system either untransfected, undifferentiated rat pheochromocytoma (PC12) cells or
APP
-baculovirus infected Sf9 cells. We have not assayed
APP
fragments for biological activity in either system. However, we have made potentially relevant observations regarding
APP
carboxyl-terminal fragment trafficking. In this note, we review our published and unpublished data in relation to published reports from other laboratories using related systems.
...
PMID:The nature and metabolism of potentially amyloidogenic carboxyl-terminal fragments of the Alzheimer beta/A4-amyloid precursor protein: some technical notes. 146 49
Phorbol esters, activators of
protein kinase C
(
PKC
), regulate the relative utilization of alternative processing pathways for the Alzheimer beta-amyloid precursor protein (beta-APP) in intact cells, increasing the production of nonamyloidogenic soluble beta-
APP
(s beta-APP) and decreasing that of neurotoxic beta-amyloid (A beta) peptide. The molecular and cellular bases of
PKC
-regulated beta-
APP
cleavage are poorly understood. Here we demonstrate in a reconstituted cell-free system that activation of endogenous
PKC
increases formation from the trans-Golgi network of secretory vesicles containing beta-
APP
and that this effect can be mimicked by purified
PKC
. The results demonstrate directly that
PKC
is involved in regulation of secretory vesicle formation and provide a mechanism by which
PKC
may reduce the formation of the A beta peptide characteristic of Alzheimer disease.
...
PMID:Regulated formation of Golgi secretory vesicles containing Alzheimer beta-amyloid precursor protein. 755 74
A large soluble N-terminal fragment of Alzheimer's disease amyloid precursor protein (secreted form of
APP
: APPs) is produced by constitutive processing in the middle of the amyloid beta-protein portion of
APP
. Recent studies indicate that the activation of endogenous
protein kinase C
(
PKC
) with phorbol ester raises the rate of secretion of APPs. We constructed rat fibroblast 3Y1 cells that stably overexpress
PKC
isoenzymes alpha, delta, or epsilon, and analyzed the amount of APPs released from these
PKC
transfectants. The levels of APPs released from 3Y1 cells overexpressing
PKC
alpha and -epsilon were higher than those from
PKC
delta-transfected and control cells expressing vector only. These results suggest that specific isoforms of
PKC
regulate the secretion of APPs through a signaling pathway.
...
PMID:Conventional protein kinase C (PKC)-alpha and novel PKC epsilon, but not -delta, increase the secretion of an N-terminal fragment of Alzheimer's disease amyloid precursor protein from PKC cDNA transfected 3Y1 fibroblasts. 775 May 71
The relative utilization of alternative processing pathways for
APP
can be regulated by the activation state of certain protein phosphorylation signal transduction pathways. For example, activation of
protein kinase C
(
PKC
), or inactivation of protein phosphatases 1 and 2A, leads to a relative increase in utilization of the nonamyloidogenic, 'alpha-secretase' cleavage pathway for
APP
processing at the expense of other pathways. The molecular and cellular basis for this regulatory event is unknown. The possible mechanisms of regulated
APP
cleavage include (either singly or in combination): 1) substrate (ie
APP
) activation; 2) substrate redistribution; 3) enzyme (ie alpha-secretase) activation; or 4) enzyme redistribution.
APP
is a phosphoprotein; however, recent evidence from studies of the metabolism of mutant
APP
molecules suggests that changes in the
APP
cytoplasmic tail phosphorylation state may not be necessary for the phosphorylation-dependent activation of 'alpha-secretase' cleavage. Further, indirect immunofluorescent studies of the subcellular distribution of
APP
in the absence or presence of phorbol esters (
PKC
activators) fail to disclose obvious phorbol-induced redistribution of
APP
immunoreactivity. Taken together, current data suggest that major candidate phosphorylation-state sensitive targets relevant to the molecular basis of
PKC
-activated processing (or 'regulated cleavage') of
APP
include the
APP
ectodomain as well as secretase enzymes and/or other components of the
APP
trafficking/processing apparatus. Progress in distinguishing among these possibilities is discussed.
...
PMID:Regulated cleavage of the Alzheimer amyloid precursor protein: molecular and cellular basis. 781 39
Protein phosphorylation mediated by phorbol ester stimulates secretion of the beta-amyloid precursor protein (beta-APP) in the cell culture. This increase in secretion is produced by a transient increase in cleavage to produce non-amyloidogenic protease nexin II products mediated by the alpha-secretase activity, and a concomitant decrease in beta-protein production. Cells expressing the Swedish familial Alzheimer's disease (FAD) variant of beta-
APP
produce more beta-protein and potentially amyloidogenic fragments than cells expressing wild-type protein; furthermore, cleavage shifts from the alpha- to the beta-secretase cleavage site of the precursor. We show that treatment with phorbol 12,13-dibutyrate (PDBu) of cells expressing the Swedish FAD reverses the mutant phenotype to wild-type. The alpha-secretase cleavage increases with a concomitant loss of beta-protein and other beta-secretase cleaved products. These results show that modulating beta-secretase cleavage directly affects beta-protein production. It suggests that activating
protein kinase C
through, for example, muscarinic receptor agonists could reduce amyloidosis by modulating the level of beta-protein produced.
...
PMID:Reversal of the Swedish familial Alzheimer's disease mutant phenotype in cultured cells treated with phorbol 12,13-dibutyrate. 797 Jan 75
Overexpression of the beta-amyloid precursor protein gene (beta-APP) may contribute to the abnormal generation of beta-amyloid protein in Alzheimer's disease. We demonstrate using a human glial cell line (1321N1) that activation of
protein kinase C
(
PKC
) with phorbol 12-myristate 13-acetate (PMA) increases beta-
APP
mRNA levels, induces known components of the transcription factor activator protein-1 (AP-1), and increases protein-DNA binding activity to AP-1 sequences within the beta-
APP
promoter. A beta-
APP
promoter-luciferase reporter gene is transcriptionally activated by PMA, as well as by expression of constitutively activated
PKC
or by expression of c-Jun. Further characterization suggests that the distal but not the proximal AP-1 recognition site binds nuclear proteins regulated by
PKC
, and that the AP-1 binding activity is likely to be composed of Jun-Jun homodimers rather than Jun-Fos heterodimers. Additional studies demonstrate that a single copy of the distal AP-1 site fused to a heterologous promoter is sufficient to confer a response to PMA. Mutagenesis of this site in the beta-
APP
promoter renders it unresponsive to c-Jun and attenuates transcriptional activation by PMA. We suggest that cellular mediators that activate
PKC
, particularly those that induce significant increases in c-Jun, may up-regulate expression of the beta-
APP
gene and consequently affect production and processing of this protein.
...
PMID:A direct role for protein kinase C and the transcription factor Jun/AP-1 in the regulation of the Alzheimer's beta-amyloid precursor protein gene. 806 12
The beta A4 peptide is the major constituent of the amyloid core of abundant senile plaques found in the cerebral cortex of patients with Alzheimer's disease. This amyloid peptide is synthesized as part of a large transmembrane amyloid protein precursor or
APP
. In addition to the highly expressed transmembrane
APP
isoforms, an mRNA encoding a secreted
APP
lacking the transmembrane domain has been identified. A cleavage of the transmembrane protein also yields an extracellular soluble
APP
fragment. The effect of phorbol esters on the release of the extracellular
APP
was studied in transfected Chinese hamster ovary cells which stably express either a transmembrane or a secreted
APP
isoform. The activation of
protein kinase C
by phorbol-12,13-dibutyrate increased the extracellular release of the transmembrane
APP
resulting from its proteolytic cleavage, while 4-beta-phorbol, which does not activate
protein kinase C
, did not significantly affect the recovery of the soluble
APP
. On the contrary, the recovery of
APP
secreted in the culture medium without proteolytic cleavage was not increased by
protein kinase C
-mediated phosphorylation.
...
PMID:Activation of protein kinase C increases the extracellular release of the transmembrane amyloid protein precursor of Alzheimer's disease. 810 Apr 50
The beta-amyloid precursor protein (beta APP) is a widely expressed integral membrane protein that is proteolytically processed to yield several secreted derivatives, including soluble
APP
(APPs), the 4-kDa amyloid beta-peptide (A beta), and a related 3-kDa peptide (p3). To understand beta APP trafficking and processing, we analyzed the sorting of beta APP in Madin-Darby canine kidney (MDCK) cells, an epithelial cell known to possess physiologically distinct apical and basolateral plasma membranes. Processing of beta APP resulted in highly polarized secretion of APPs. More than 90% of APPs was detected in the basolateral compartment, and less than 10% was found in the apical compartment. This was associated with a preferential localization of beta APP on the basolateral cell surface. Activation of
protein kinase C
, which is known to enhance the secretion of APPs, did not change the polarity of APPs release but significantly increased the amount secreted. A beta and p3 peptides were also secreted predominantly basolaterally. In addition, MDCK cells secreted a truncated form of A beta beginning at Arg-5. These data show that the proteolytic processing products of beta APP undergo polarized secretion. Moreover, the results suggest that the amyloidogenic A beta peptide is generated following the polarized sorting of beta APP. The polarized basolateral secretion of A beta in these epithelial cells provides a potential mechanism for the accumulation of A beta in the abluminal basement membrane of brain microvessels during Alzheimer disease.
...
PMID:Polarized secretion of beta-amyloid precursor protein and amyloid beta-peptide in MDCK cells. 810 45
A compromise or deregulation in signal transduction cascades could adversely affect cellular functions and possibly contribute to cell death. In recent years, it has become increasingly apparent that pronounced activation of neuronal signal transduction systems is a characteristic of AD brain. There is evidence that signal transduction systems play a role in the formation or development of these pathological features of AD. Aberrant activity and localization of components of signaling mechanisms (growth factors, their receptors, protein kinases, phosphoprotein phosphatases, and phosphoproteins) are closely associated with the intracellular accumulation of PHF, the extracellular deposition of amyloid, and the formation of neuritic plaques in AD brain. In particular, immunohistochemical studies reveal increased levels of neuronal staining for
APP
, possibly an important growth factor in AD, both in frontal cortex and hippocampus. Anti-
APP
immunostaining is also associated with the neuritic component of plaques. Additionally,
PKC
(beta II) immunostaining is increased in the neuronal cell body and neuropil of AD samples, particularly in association with plaques, suggesting a postsynaptic involvement of this enzyme. On the other hand,
PKC
(beta I) immunostaining is associated with axonal staining particularly in the sprouting neurites of plaques. Sprouting neuritic components of plaques are immunopositive with other growth-associated proteins, such as GAP43, MARCKS, and spectrin. Immunoreactivity of other members of signal transduction systems such as Fos and stathmin are all increased in AD hippocampal neurons. On the other hand, several protein kinases and phosphoproteins were immunolocalized to tangles. Thus, the hyperactivation and dysfunction of signal transduction systems could be involved in the pathogenesis of AD.
...
PMID:Hyperactivation of signal transduction systems in Alzheimer's disease. 823 9
We have studied the activation of human ml-muscarinic receptors in a genetically engineered Chinese hamster ovary cell line (CHO-ml) to determine which second messenger systems affect the secretion of
APP
via the non-amyloidogenic route. Carbachol activation of the signaling pathways in CHO-ml cells promotes
APP
secretion by activation of both
protein kinase C
(
PKC
)-dependent or Ca(++)-dependent second messenger pathways. Both pathways converge to increase the enzyme activity of phospholipase A2 (PLA2), the enzyme that releases arachidonic acid from cellular stores. Directly activating PLA2 with melittin, a peptide from bee venom, or by adding arachidonic acid directly to cultured cells increases the secretion of
APP
. Thus, our results indicate that arachidonic acid is yet another cellular second messenger involved in regulating the metabolism of
APP
in addition to
PKC
and cytoplasmic Ca++. Moreover, activation of PLA2 appears to be an obligatory event in increasing the secretion of
APP
from CHO-ml cells by the various methods of activation that we have tried thus far.
...
PMID:The role of arachidonic acid in the secretion of the amyloid precursor protein (APP). 862 5
1
2
3
4
5
6
Next >>